Contineum Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Contineum Therapeutics, Inc. (CTNM) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-42.2622.72-24.25-29.00
Depreciation & Amortization0.260.200.330.33
Stock Based Compensation6.802.221.931.75
Change in Working Capital5.33-1.02-1.270.11
Change in Accounts Payable1.140.00-0.23-0.11
Change in Other Working Capital0.87-2.102.900.16
Other Operating Activities0.87-2.102.900.16
Net Cash from Operating Activities-32.8519.35-20.12-26.27
Investing Activities
Capital Expenditures-0.51-0.41-0.12-0.17
Acquisitions0.020.000.000.00
Purchases of Investments-226.41-141.87-64.70-66.78
Sales/Maturities of Investments157.1676.7187.121.98
Net Cash from Investing Activities-69.74-65.5722.30-64.97
Financing Activities
Debt Repayment0.00-3.75-1.250.00
Common Stock Issued108.210.160.020.11
Common Stock Repurchased0.00-0.030.000.00
Other Financing Activities0.79-0.340.000.00
Net Cash from Financing Activities109.0056.18-1.2479.84
Summary
Net Change in Cash6.429.960.94-11.40
Cash at Beginning of Period15.535.574.6316.03
Cash at End of Period21.9415.535.574.63
Free Cash Flow-33.3618.94-20.24-26.43
Supplemental Disclosures
Interest Paid0.000.150.230.22
Income Taxes Paid0.000.450.000.00